The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer.
 
James William Welsh
Employment - MD Anderson Cancer Center; MD Anderson Cancer Center
Leadership - MolecularMatch; MolecularMatch
Stock and Other Ownership Interests - MolecularMatch
Honoraria - Aileron Therapeutics; American Association of Physicists in Medicine; Nanobiotix; Shandong Cancer Hospital; The Korean Society for Radiation Oncology
Consulting or Advisory Role - Checkmate Pharmaceuticals; Mavu Pharmaceutical; MolecularMatch; Oncorena; Reflexion Medical
Research Funding - Aileron Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Mavu Pharmaceutical; Merck; Nanobiotix
Travel, Accommodations, Expenses - AACR; Aileron Therapeutics; American Society for Radiation Oncology; Gustave Roussy Cancer Center; IASLC; MedAustron; Nanobiotix; Radiation Research Society; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; Turkish Society of Lung Cancer
 
Hari Menon
No Relationships to Disclose
 
Chad Tang
Stock and Other Ownership Interests - Corvus Pharmaceuticals
Honoraria - Reflexion Medical
 
Vivek Verma
No Relationships to Disclose
 
Mehmet Altan
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
 
Kenneth R. Hess
No Relationships to Disclose
 
Patricia de Groot
No Relationships to Disclose
 
Quynh Nguyen
No Relationships to Disclose
 
George R. Simon
Honoraria - AstraZeneca; Celgene
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Lilly; MD Anderson Physician’s Network; Merck Serono; Takeda
Speakers' Bureau - AstraZeneca; Celgene; DAVA Pharmaceuticals; Nexus Pharmaceuticals Inc; OncLive
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Celgene; Genentech/Roche; Lilly; Merck Serono
 
Ferdinandos Skoulidis
Honoraria - Bristol-Myers Squibb
 
Joe Y. Chang
Stock and Other Ownership Interests - Global Advisory Board Medi-Globe
Honoraria - Varian Medical Systems
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Varian Medical Systems
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations